Skip to main content
Fig.Ā 2 | Clinical Sarcoma Research

Fig.Ā 2

From: A clinico-genomic analysis of soft tissue sarcoma patients reveals CDKN2A deletion as a biomarker for poor prognosis

Fig.Ā 2

Clinical outcomes for localized soft tissue sarcomas with genomic sequencing treated at Stanford (nā€‰=ā€‰96). a Forest plot of most commonly altered 8 genes with prognosis reveals only CDKN2A to be significantly associated with worse prognosis. b Kaplanā€“Meier plot of overall survival for CDKN2A altered vs. non-CDKN2A altered patients (pā€‰=ā€‰0.017). c Histologic distribution of all patients (d) and CDKN2A altered patients (C2) reveals increases in representation of MPNST, MFS, and UPS with decreases in LMS and LPS. e Kaplanā€“Meier plot of time to recurrence for CDKN2A altered vs. non-CDKN2A altered patients (pā€‰=ā€‰0.09). f Kaplanā€“Meier plot of time to treatment failure for first line systemic chemotherapy for CDKN2A altered vs. non-CDKN2A altered patients (pā€‰=ā€‰0.29)

Back to article page